Top Markets
Coin of the day
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc.

VICP
Rank in Stocks #25708
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
Share Price
$1.45
Last synced: 2026-08-19
Market Cap
$46.94M
Change (1 day)
0.00%
Change (1 year)
-18.08%
Country
US
Trade Vicapsys Life Sciences, Inc. (VICP)

Category

EPS for Vicapsys Life Sciences, Inc. (VICP)
EPS as of 2026 TTM: 0
According to Vicapsys Life Sciences, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Vicapsys Life Sciences, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$-7.98 -
US